Matthew E. ColdironLorenz Von SeidleinRebecca F. GraisEpicentreMahidol University2018-12-212019-03-142018-12-212019-03-142017-11-28Malaria Journal. Vol.16, No.1 (2017)147528752-s2.0-85035797251https://repository.li.mahidol.ac.th/handle/123456789/42722© 2017 The Author(s). Seasonal malaria chemoprevention (SMC) was recommended in 2012 for young children in the Sahel during the peak malaria transmission season. Children are given a single dose of sulfadoxine/pyrimethamine combined with a 3-day course of amodiaquine, once a month for up to 4 months. Roll-out and scale-up of SMC has been impressive, with 12 million children receiving the intervention in 2016. There is evidence of its overall benefit in routine implementation settings, and a meta-analysis of clinical trial data showed a 75% decrease in clinical malaria compared to placebo. SMC is not free of shortcomings. Its target zone includes many hard-to-reach areas, both because of poor infrastructure and because of political instability. Treatment adherence to a 3-day course of preventive treatment has not been fully documented, and could prove challenging. As SMC is scaled up, integration into a broader, community-based paradigm which includes other preventive and curative activities may prove beneficial, both for health systems and for recipients.Mahidol UniversityImmunology and MicrobiologyReviewSCOPUS10.1186/s12936-017-2132-1